29 patents
Utility
Farnesoid X receptor agonists and uses thereof
3 Oct 23
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Karensa L. Douglas, Andiliy G. Lai
Filed: 16 Jun 21
Utility
Crystalline Forms of a Farnesoid X Receptor Agonist
11 May 23
Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
3pxzpib3t4owbxownxx0dawzz5fydcja0jtozp747mbq9so8n562crxisl9s
27 Apr 23
Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Mar 21
Utility
3id6s43egzg09ihnxb9n6lom2khugxpimbse0kz1ui6ed
20 Apr 23
Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
asr9ppppr3wi1w bmp53hntm7utqu19cz4dvm1en28e2qlhkp
13 Oct 22
Described herein are combination therapies with farnesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER
Filed: 9 Jun 22
Utility
dgdmj2qiv6z1udtfwvn4i0ixd3porhtygzvfbj2
24 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 30 Nov 21
Utility
ntbvfg16v0j3toy1kucnohba8fe4lfdr837bh
17 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 22 Nov 21
Utility
bdf4uh71b0prmrpgpclc522f3cx
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK
Filed: 17 Sep 19
Utility
jvc2cxjgab60whggli2izice40l0z3eh7dk1zwzqcsw5ksrqzsl05u z8
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Andiliy G. LAI, Karensa L. DOUGLAS
Filed: 17 Sep 19
Utility
2g5kkwxxjk5xhqjrnh3n22t3jkvn38n6wlqhxoyj18g5abwg9o1w xetj
17 Feb 22
Described herein are combination therapies with famesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with famesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Sep 19
Utility
wns6v1nvvnmfsibew9382rgl8us sfhzr
1 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa, Karensa L. Douglas, Andiliy G. Lai
Filed: 14 Mar 18
Utility
34z4ycnifqq h7eee8rpjrnd6nacf6hidbaek4
6 Jan 22
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
Nicholas D. SMITH, Andrew R. HUDSON, Mi CHEN, Johnny Y. NAGASAWA, Iriny BOTROUS
Filed: 23 Oct 19
Utility
c80jmfv2xqg801cy083idkewp01702sljwzzshohceuh88quv
4 Jan 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 12 May 20
Utility
uaf0hv1rbpnacsna502vehmah14tb4h1vpv80xhpgzz
23 Dec 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 16 Jun 21
Utility
g1a7onl6j6mria3i9w0fi9uejndprx3g3vq55ejm6rv
11 Nov 21
Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Sep 19
Utility
vue5fjfjyzr7jx7y052px34nz4cgt5cd4safb h12pk
30 Sep 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 19 Jan 21
Utility
nysml03xs8zlqsmk1o00x8plxgcrrq9v6dp4u2p9vyt33v79l5n
10 Aug 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Karensa L. Douglas, Andiliy G. Lai
Filed: 17 Sep 19
Utility
vt11zigc94f1ttpmefyaeezf5twxi5ipq1p4l2aklww
30 Mar 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 14 Mar 18
Utility
vt7 8g64dtguzhsh24ncg25f18qvh
23 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Stephen P. Govek, Johnny Y. Nagasawa
Filed: 28 May 20
Utility
fgtlcripdj86x 8tmx4tj4
4 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 12 May 20